192 related articles for article (PubMed ID: 8363226)
21. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
Lambe CU; Averett DR; Paff MT; Reardon JE; Wilson JG; Krenitsky TA
Cancer Res; 1995 Aug; 55(15):3352-6. PubMed ID: 7614470
[TBL] [Abstract][Full Text] [Related]
22. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of myeloid leukemia cells to calcium influx blockade: application to bone marrow purging.
Soboloff J; Zhang Y; Minden M; Berger SA
Exp Hematol; 2002 Oct; 30(10):1219-26. PubMed ID: 12384154
[TBL] [Abstract][Full Text] [Related]
24. Autologous bone marrow transplantation for leukemia.
Stuart RK
Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
[TBL] [Abstract][Full Text] [Related]
25. Purging in autologous hematopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide (4-HC).
Hatta Y; Itoh T; Baba M; Miyajima T; Shimojima H; Sawada U; Horie T
Leuk Res; 2002 May; 26(5):477-82. PubMed ID: 11916522
[TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P
Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103
[TBL] [Abstract][Full Text] [Related]
28. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
29. An effective immunomagnetic method for bone marrow purging in T cell malignancies.
Wang MY; Kvalheim G; Kvaløy S; Beiske K; Jakobsen E; Wijdenes J; Pihl A; Fodstad O
Bone Marrow Transplant; 1992 May; 9(5):319-23. PubMed ID: 1617315
[TBL] [Abstract][Full Text] [Related]
30. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
Gandhi V; Plunkett W; Rodriguez CO; Nowak BJ; Du M; Ayres M; Kisor DF; Mitchell BS; Kurtzberg J; Keating MJ
J Clin Oncol; 1998 Nov; 16(11):3607-15. PubMed ID: 9817282
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
Bishop MR; Jackson JD; Tarantolo SR; O'Kane-Murphy B; Iversen PL; Bayever E; Joshi SM; Sharp JG; Pierson JL; Warkentin PI; Armitage JO; Kessinger A
J Hematother; 1997 Oct; 6(5):441-6. PubMed ID: 9368180
[TBL] [Abstract][Full Text] [Related]
33. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
34. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
Makrynikola V; Kabral A; Bradstock KF
Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic potential of anti-CD7 immunotoxin (WT1-ricin A) to purge ex vivo malignant T cells in bone marrow.
Preijers FW; De Witte T; Wessels JM; Meyerink JP; Haanen C; Capel PJ
Br J Haematol; 1989 Feb; 71(2):195-201. PubMed ID: 2784323
[TBL] [Abstract][Full Text] [Related]
36. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation.
Long GS; Hiserodt JC; Harnaha JB; Cramer DV
Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797
[TBL] [Abstract][Full Text] [Related]
37. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
Montgomery RB; Kurtzberg J; Rhinehardt-Clark A; Haleen A; Ramakrishnan S; Olsen GA; Peters WP; Smith CA; Haynes BF; Houston LL
Bone Marrow Transplant; 1990 Jun; 5(6):395-402. PubMed ID: 2369680
[TBL] [Abstract][Full Text] [Related]
38. Purging in autologous and allogeneic bone marrow transplantation.
Gulati SC; Lemoli RM; Acaba L; Igarashi T; Wasserheit C; Fraig M
Curr Opin Oncol; 1992 Apr; 4(2):264-71. PubMed ID: 1591301
[TBL] [Abstract][Full Text] [Related]
39. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
40. Future paradigm for autologous bone marrow transplantation: tumor purging and ex vivo production of normal stem and progenitor cells.
Rummel SA; Van Zant G
J Hematother; 1994; 3(3):213-8. PubMed ID: 7827869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
